Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2
Zealand Pharma appears to have taken a small step forward with a candidate that targets both GLP-1 and GLP-2, an approach that aims to ease
→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether.
An FDA advisory committee mostly agreed on Friday that an investigational once-weekly insulin product carries too much risk for adults with type 1 diabetes to
The CDC is preparing for the possibility of H5N1 posing an increased risk to human health, even though that current risk remains low, the agency
An estimated 750,000 deaths linked to antimicrobial resistance (AMR) could be prevented every year through available vaccines, water and sanitation, and infection control methods, according
CHICAGO — Vaccination against human papillomavirus (HPV) reduced the risk of multiple types of cancer in both men and women, a large retrospective cohort study
Springtime is associated with renewal, as nature emerges from its winter slumber, accompanied by the return of color, a chorus of birdsong, and the delicate
CHICAGO — The vast majority of young breast cancer survivors who attempted pregnancy after treatment were able to become pregnant and have a live birth,
WASHINGTON — While rates of gallbladder cancer have been decreasing in the U.S., this rare but often-deadly cancer is on the rise in Black patients,